全身性糖皮质激素对成年危重症患者消化道出血发生率的影响:系统评价与荟萃分析
该系统评价与荟萃分析纳入比较全身性糖皮质激素(用药超过24小时)与安慰剂/无治疗的随机临床试验,评估成年危重症患者90天内消化道出血发生率。25项试验(n=14,615)报告主要结局,糖皮质激素组临床重要消化道出血发生率为2.3%,对照组为1.8%(RR 1.26;95%CI 1.01-1.57;I²=0%;TSA校正CI 0.51-3.14);55项试验(n=21,792)报告次要结局,任何严重程度消化道出血风险无差异(RR 1.10;95%CI 0.92-1.32;I²=0%;TSA校正CI 0.87-1.38)。GRADE证据质量为低(偏倚风险和不精确性)。作者结论认为糖皮质激素可能轻度增加临床重要消化道出血发生率,但不增加任何严重程度的出血。
要点
- 成年危重症患者使用全身性糖皮质激素超过24小时,临床重要消化道出血合并发生率为2.3%,对照组为1.8%(RR 1.26;95%CI 1.01-1.57)。
- 任何严重程度消化道出血风险无差异:糖皮质激素组与对照组相比RR 1.10(95%CI 0.92-1.32),未达统计学显著。
- 主要结局TSA校正CI为0.51-3.14,提示随机误差风险影响结论稳健性。
- GRADE证据质量为低,降级原因为偏倚风险和不精确性。
- 事件罕见、试验报告不频繁和高偏倚风险降低了证据质量。
适用人群与场景
- 成年危重症患者,接受全身性糖皮质激素治疗超过24小时者。
研究设计与关键结果
- 系统评价与荟萃分析,纳入比较全身性糖皮质激素(用药超过24小时)与安慰剂/无治疗的随机临床试验。
- 25项试验(n=14,615)报告主要结局(90天内临床重要消化道出血):糖皮质激素组2.3% vs 对照组1.8%,RR 1.26(95%CI 1.01-1.57;I²=0%;TSA校正CI 0.51-3.14)。
- 55项试验(n=21,792)报告次要结局(90天内任何严重程度消化道出血):RR 1.10(95%CI 0.92-1.32;I²=0%;TSA校正CI 0.87-1.38),无差异。
- GRADE证据质量为低(偏倚风险和不精确性)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机临床试验。
- GRADE证据质量:低(偏倚风险和不精确性)。
- 局限:事件罕见、试验报告不频繁和高偏倚风险降低了证据质量。
对床旁实践的改变
- 作者认为,成年危重症患者中糖皮质激素可能轻度增加临床重要消化道出血发生率,但不增加任何严重程度的出血。
- 证据质量低,事件罕见,临床决策需结合个体出血风险权衡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To assess the effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in adult critically ill patients.
METHODS: We systematically reviewed randomised clinical trials comparing systemic corticosteroids administered for more than 24 h with placebo/no treatment in adult critically ill patients. Trial selection, data abstraction and risk of bias assessments were performed in duplicate. We used trial sequential analysis (TSA) to assess the risk of random errors and the grading of recommendations, assessment, development, and evaluations (GRADE) approach to assess the quality of evidence. The primary outcome was the incidence of clinically important gastrointestinal bleeding within 90 days. The secondary outcome was the incidence of gastrointestinal bleeding of any severity within 90 days.
RESULTS: Twenty-five trials (n = 14,615) reported data for the primary outcome and 55 trials (n = 21,792) for the secondary outcome. The pooled incidence of clinically important gastrointestinal bleeding was 2.3% in the corticosteroid group and 1.8% in the control group (RR, 1.26; 95% CI, 1.01-1.57; I2 = 0%, TSA-adjusted CI 0.51-3.14). We observed no difference in the risk of gastrointestinal bleeding of any severity (RR, 1.10; 95% CI, 0.92-1.32; I2 = 0%, TSA-adjusted CI 0.87-1.38). The GRADE quality of evidence was low (risk of bias and imprecision).
CONCLUSIONS: We observed an overall low incidence of clinically important gastrointestinal bleeding among adult critically ill patients. Corticosteroids may slightly increase the incidence of clinically important gastrointestinal bleeding, but not bleeding of any severity. Rarity of events, infrequent trial reporting and high risk of bias reduced the quality of evidence.
参考来源
- Butler E, Møller MH, Cook O, et al. The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis. Intensive Care Med. 2019. PMID: 31501997. doi:10.1007/s00134-019-05754-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。